Drug intelligence / Profile preview

autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3

Development stage: Phase 2
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular, Intradiscal

Overview

Autologous adipose-derived mesenchymal stem cell (Ad-MSC) spheroids pretreated with matrillin 3 are an investigational regenerative therapy designed for cartilage repair and regeneration. In this approach, a patient's own Ad-MSCs are formed into three-dimensional spheroids and exposed to matrillin 3, an extracellular matrix protein known to enhance chondrogenic differentiation and suppress hypertrophic changes in the cells. This pretreatment modulates the therapeutic effect of Ad-MSCs by increasing expression of chondrogenic markers (such as SOX9, collagen II, aggrecan) while reducing markers associated with hypertrophy and ossification (such as collagen X, RUNX2, ALP). The resulting product is intended for intra-articular or intradiscal administration to promote hyaline-like cartilage regeneration and prevent subchondral bone sclerosis in conditions such as osteoarthritis or chronic discogenic low back pain[1][2][4][5].

Other names: matrilin-3-primed adipose-derived mesenchymal stem cell spheroidmatrilin3-primed adipose-derived mesenchymal stem cell spheroidmatrilin 3-primed adipose-derived mesenchymal stem cell spheroidmatrilin-3-pretreated Ad-MSC spheroidmatrilin3-pretreated Ad-MSC spheroidmatrilin 3-pretreated Ad-MSC spheroid

Beyond the preview

Go deeper on autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3.

Explore the full profile